头颈部鳞状细胞癌患者同步放化疗中每3周或每周顺铂方案的多中心回顾性分析
该多中心回顾性分析纳入瑞士3个中心2008年6月至2015年12月接受顺铂同步放化疗的314例头颈部鳞状细胞癌患者,比较每3周方案(N=127)与每周方案(N=187)的累积剂量和毒性。每3周组累积剂量≥200 mg/m2的比例更高(75.6% vs 47.1%,p<0.001),急性肾毒性发生率也更高(33.1% vs 20.9%,p=0.022),但未证实累积剂量≥200 mg/m2与更好生存相关(HR 1.3,95%CI 0.8-1.9)。
要点
- 每3周顺铂组累积剂量≥200 mg/m2的比例显著高于每周组(75.6% vs 47.1%,p<0.001)。
- 每3周方案急性肾毒性发生率高于每周方案(33.1% vs 20.9%,p=0.022)。
- 累积顺铂剂量≥200 mg/m2与更好生存的关联在本研究中未得到证实(HR 1.3,95%CI 0.8-1.9)。
核心结论
- 接受每3周顺铂方案的患者达到累积剂量≥200 mg/m2的比例显著高于每周方案。
- 既往报告的累积顺铂剂量≥200 mg/m2与更好结局的关联在本研究中未能得到证实。
研究设计与样本
- 多中心回顾性分析,纳入瑞士3个中心2008年6月至2015年12月接受顺铂同步放化疗的全部患者。
- 共纳入314例患者,其中每3周方案组127例,每周方案组187例。
主要发现
- 每3周组中位累积顺铂剂量为200 mg/m2(IQR 150-300),每周组为160 mg/m2(IQR 120-240)。
- 每3周组达到累积剂量≥200 mg/m2的比例为75.6%,每周组为47.1%(p<0.001)。
- 调整年龄和性别后的多变量分析仍观察到该关联(OR 3.46,95%CI 2.1-5.7)。
- 每3周组急性肾毒性发生率为33.1%,每周组为20.9%(p=0.022)。
- 界标分析未能证实顺铂剂量≥200 mg/m2与更好生存相关(HR 1.3,95%CI 0.8-1.9)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concurrent chemoradiotherapy with cisplatin is standard for patients (pts) with loco-regionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) and for patients with resected SCCHN with high-risk features. The standard regimen includes 3-weekly cisplatin, but weekly regimens are often used to lower toxicity. Reaching a cumulative dose of ≥200 mg/m2 cisplatin was shown being associated with improved outcome. We herein investigated cumulative dose reached and toxicities between the 3-weekly and weekly cisplatin regimens with concurrent radiotherapy. METHODS: Multicentre, retrospective analysis of all patients undergoing combined RCT with cisplatin treated at 3 centres in Switzerland between 06/2008 and 12/2015. RESULTS: Three hundred fourteen pts. were included (3-weekly, N = 127; weekly, N = 187). Median cumulative cisplatin dose was 200 mg/m2 (IQR 150-300) for pts. treated with a 3-weekly schedule and 160 mg/m2 (120-240) for the weekly schedule, consequently more pts. treated with a 3-weekly schedule reached a cumulative dose ≥200 mg/m2 (75.6% vs. 47.1%, p < 0.001). This association was also observed in multivariable analysis adjusted for age and sex (OR 3.46, 95% confidence interval [CI], 2.1-5.7). The 3-weekly regimen led to a higher rate of acute renal toxicity (33.1% vs. 20.9%, p = 0.022). In the landmark analysis, we could not confirm that a cisplatin dose ≥200 mg/m2 is associated with better survival (HR 1.3, 95% CI 0.8-1.9). CONCLUSIONS: Significantly more patients receive a cumulative cisplatin dose of ≥200 mg/m2, when treated with a 3-weekly schedule compared to weekly dosing. The previously reported association between a cumulative cisplatin dose ≥200 mg/m2 and improved outcome could not be shown in our study.
引用
- Helfenstein S, Riesterer O, Meier UR, et al. 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck - a multicentre, retrospective analysis. Radiat Oncol. 2019. PMID: 30744643. doi:10.1186/s13014-019-1235-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。